Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

MONOCLONAL ANTIBODIES AND ANTIBODY-DRUG CONJUGATES IN PRECISION CANCER THERAPY

Dr. Jonathan E. Parker
Department of Pharmaceutical Sciences,
Institute for Translational Biomedical Research, USA
jonathan.parker@example.org

Abstract.

Precision oncology increasingly relies on therapeutic platforms that couple molecular recognition with mechanism-specific killing. Monoclonal antibodies (mAbs) provide high-affinity recognition of tumor-associated antigens and can inhibit signaling, recruit immune effector functions or block immune checkpoints, whereas antibody-drug conjugates (ADCs) extend this concept by attaching a potent cytotoxic payload to a tumor-targeting antibody through a chemically engineered linker. This structured review evaluates how antibody biology, antigen selection, linker chemistry, payload class, drug-to-antibody ratio, internalization, bystander activity and biomarker stratification determine the therapeutic index of modern antibody-based cancer therapy. Literature was selected from peer-reviewed international sources emphasizing recent reviews and landmark phase III trials. The evidence indicates that precision selection of target and molecular format is as important as payload potency. New-generation ADCs can produce activity in tumors with heterogeneous or relatively low antigen expression, but their benefits are constrained by interstitial lung disease, myelosuppression, neuropathy, ocular toxicity, antigen loss, altered intracellular trafficking and multidrug resistance. Clinical examples including trastuzumab deruxtecan, trastuzumab emtansine, sacituzumab govitecan and enfortumab vedotin demonstrate that antibody-guided cytotoxic delivery can extend the clinically actionable range of tumor biomarkers. Future progress is likely to depend on site-specific conjugation, improved linker stability, novel payloads, bispecific and dual-payload ADCs, biomarker-adaptive dosing, and integration of spatial and longitudinal tumor profiling. These developments position antibody therapeutics as a central component of precision cancer medicine while emphasizing the need for individualized risk-benefit assessment.

Keywords: monoclonal antibodies; antibody-drug conjugates; precision oncology; targeted therapy; linker; payload; biomarker; resistance; therapeutic index

1. INTRODUCTION

Cancer therapy has progressively shifted from histology-dominated treatment toward biomarker-guided selection of therapies that exploit specific molecular vulnerabilities. Therapeutic antibodies are particularly suited to this strategy because they combine high target specificity with modular Fc-mediated functions, receptor blockade and the

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

possibility of engineering additional therapeutic functions (1). In oncology, established monoclonal antibodies can neutralize growth-factor signaling, induce antibody-dependent cellular cytotoxicity, trigger complement activity, block angiogenesis or modify immune checkpoints. Their clinical value, however, depends on whether the selected antigen is sufficiently tumor-associated, biologically relevant and accessible to the therapeutic molecule (1,2).

Antibody-drug conjugates add a second precision layer by covalently linking a tumor-targeting antibody to a highly potent cytotoxic payload. The conceptual objective is to concentrate drug exposure in antigen-expressing malignant tissue while limiting systemic exposure of normal organs. The activity of an ADC is therefore not determined by the antibody alone: antibody affinity, internalization, linker stability, payload permeability, drug-to-antibody ratio (DAR), Fc properties and tumor microenvironment all interact to shape efficacy and toxicity (2-5). Recent generations of ADCs have expanded the concept beyond strongly antigen-positive tumors and have demonstrated activity in settings characterized by heterogeneous or low-level target expression, in part because membrane-permeable payloads can mediate a bystander effect (3,7).

The rapid evolution of ADCs has also revealed important limitations. Off-target and on-target toxicities can resemble the effects of the payload or arise from complex distribution and catabolism of the conjugate. Interstitial lung disease, myelosuppression, gastrointestinal toxicity, peripheral neuropathy and ocular toxicities are examples of clinically relevant complications associated with different ADC platforms (4). Resistance can occur through target downregulation, altered receptor trafficking, lysosomal dysfunction, increased drug efflux or payload-specific resistance mechanisms (13). Accordingly, precision therapy requires not merely matching a drug to a biomarker, but understanding the full target-conjugate-patient system.

The aim of this article is to synthesize current evidence on monoclonal antibodies and ADCs in precision cancer therapy, with emphasis on molecular design, patient selection, clinical translation, resistance and safety. The article uses an IMRAD structure adapted for a structured narrative review and highlights design principles that can support future development of more effective and individualized antibody therapeutics.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026




Figure 1. Conceptual continuum linking tumor biomarker profiling to monoclonal antibody and ADC-based precision therapy.

2. MATERIALS AND METHODS

2.1. Review design and literature selection

A structured narrative review approach was used. Peer-reviewed literature was identified through targeted searches of PubMed and major journal platforms using combinations of the terms monoclonal antibody, antibody-drug conjugate, precision oncology, linker, payload, drug-to-antibody ratio, bystander effect, resistance, safety, HER2, TROP2 and Nectin-4. Priority was given to high-impact reviews, mechanistic studies and landmark randomized clinical trials published from 2016 through 2026. Older sources were retained only when they addressed foundational ADC chemistry or resistance mechanisms. Fifteen international sources were selected for the reference set and are cited numerically in the text as (1), (2) and so forth.

2.2. Analytical framework

Evidence was organized into five domains: (i) mechanisms and therapeutic formats of monoclonal antibodies; (ii) ADC molecular architecture and intracellular pharmacology; (iii) biomarker-driven patient selection and representative clinical evidence; (iv) resistance and toxicity mechanisms; and (v) strategies for next-generation precision optimization. No meta-analysis was attempted because the included studies differed in tumor type, line of therapy, biomarker definition, ADC chemistry and clinical end points. Quantitative trial findings were interpreted qualitatively rather than pooled across indications.

2.3. Assessment criteria

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

For each therapeutic approach, the review considered target specificity, target density and heterogeneity, dependence on internalization, contribution of immune effector mechanisms, linker behavior, payload class, potential for bystander killing, known resistance mechanisms and clinically important toxicities. Clinical evidence was interpreted in relation to the biological rationale of the platform. The primary goal was to identify generalizable principles rather than to rank individual agents.

3. RESULTS

3.1. Monoclonal antibodies as precision therapeutics

Monoclonal antibodies can act through direct and immune-mediated mechanisms. Receptor-blocking antibodies suppress oncogenic signaling or ligand-receptor interactions, whereas Fc-competent antibodies can recruit natural killer cells and macrophages through Fc gamma receptors. Checkpoint-blocking antibodies act differently: rather than directly killing the tumor, they release inhibitory signals that restrain antitumor T cells. Bispecific antibodies further broaden this platform by simultaneously recognizing two epitopes or bridging tumor cells to immune effectors (1,11). These distinctions are important because the same tumor biomarker can support different therapeutic formats depending on its biology and cell-surface behavior.

Table 1. Major antibody-based therapeutic formats in precision oncology.

Therapeutic format	Primary mechanism	Precision requirement	Representative application
Naked mAb	Receptor blockade and/or Fc-mediated immune killing	High-quality antigen expression and biological dependence	HER2, CD20, EGFR-directed therapy
Immune-checkpoint mAb	Release of inhibitory immune signaling	Tumor/host immune context and predictive biomarkers	PD-1/PD-L1 or CTLA-4 blockade
Bispecific antibody	Dual recognition or immune-cell redirection	Compatible antigen pair and manageable cytokine-mediated toxicity	T-cell engagement and dual-target blockade
Antibody-drug conjugate	Targeted delivery of a cytotoxic payload	Surface antigen, internalization/processing and payload sensitivity	HER2, TROP2, Nectin-4 and hematologic targets

3.2. ADC architecture: antibody, linker, payload and DAR

The ADC is a multicomponent pharmacological system rather than a simple antibody carrying chemotherapy. The antibody determines tissue recognition, circulation behavior

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

and internalization. The linker must remain sufficiently stable in plasma while allowing efficient intracellular payload release. Cleavable linkers can respond to lysosomal enzymes, acidic conditions or reducing environments, whereas non-cleavable linkers require intracellular proteolysis of the antibody scaffold. The payload must be highly potent because only a limited number of molecules are delivered per antibody, and its membrane permeability influences whether neighboring antigen-low tumor cells can be killed through a bystander effect (3,5).

DAR influences potency, solubility, aggregation and pharmacokinetics. Excessive loading can increase hydrophobicity, accelerate clearance and increase off-target toxicity, whereas low loading can reduce cytotoxic delivery. Modern site-specific conjugation approaches aim to generate more homogeneous products and improve the relationship between exposure and pharmacological effect (3,5). This engineering perspective is central to precision therapy because the therapeutic index emerges from the integrated behavior of all ADC components, not from antigen expression alone.

Table 2. Key ADC design variables and their pharmacological consequences.

Design variable	Desired property	Potential consequence if suboptimal
Antibody/target	Tumor-selective antigen recognition with suitable internalization	Off-tumor binding, weak uptake or variable exposure
Linker	Plasma stability with efficient intracellular release	Premature payload release or insufficient intracellular liberation
Payload	High potency with mechanism appropriate to tumor biology	Narrow therapeutic index or payload-specific resistance
DAR/conjugation	Controlled, reproducible loading with acceptable hydrophobicity	Aggregation, rapid clearance, heterogeneous pharmacology
Bystander potential	Useful diffusion when antigen expression is heterogeneous	Collateral toxicity if payload escapes beyond tumor tissue

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026




Figure 2. Simplified mechanism of ADC action from antigen recognition to intracellular payload release and tumor-cell killing.

3.3. Clinical translation and biomarker expansion

Clinical trials illustrate how ADC design can expand the therapeutic meaning of a biomarker. Trastuzumab emtansine established the feasibility of HER2-targeted delivery of a microtubule inhibitor. Trastuzumab deruxtecan subsequently demonstrated that a different linker-payload architecture and a membrane-permeable topoisomerase I inhibitor could produce major activity in HER2-positive disease and, importantly, in HER2-low metastatic breast cancer (7,8). This observation altered the concept of HER2 from a binary amplification-based biomarker toward a broader continuum of therapeutically actionable expression in selected settings.

The same principle is visible outside HER2. Sacituzumab govitecan targets TROP2 and delivers SN-38, producing clinically meaningful benefit in metastatic triple-negative breast cancer (9). Enfortumab vedotin targets Nectin-4 and has shown survival benefit in advanced urothelial carcinoma after prior systemic therapy (10). These examples demonstrate that the antibody determines where the conjugate concentrates, whereas the linker and payload determine how efficiently target engagement is translated into tumor killing.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

Table 3. Representative antibody-drug conjugates illustrating precision oncology principles.

ADC	Target / payload concept	Representative setting	Precision lesson
Trastuzumab emtansine	HER2 / microtubule-directed payload	HER2-positive breast cancer	Strong target dependence and validated HER2 biology
Trastuzumab deruxtecan	HER2 / topoisomerase I payload; bystander-capable design	HER2-positive and HER2-low breast cancer	Architecture can extend activity to lower/heterogeneous antigen expression
Sacituzumab govitecan	TROP2 / SN-38	Metastatic triple-negative breast cancer	Broadly expressed surface antigen can support targeted cytotoxic delivery
Enfortumab vedotin	Nectin-4 / auristatin-class payload	Advanced urothelial carcinoma	Target prevalence plus potent payload can create a clinically useful therapeutic window

3.4. Safety and therapeutic index

The ideal ADC would deliver most of its cytotoxic activity inside tumor tissue; clinically, this separation is incomplete. Safety depends on target distribution in normal tissues, stability of the linker, nonspecific uptake, Fc-mediated disposition, payload properties and patient-specific vulnerability (4,12). Toxicity patterns often resemble the pharmacology of the released payload. For example, topoisomerase I inhibitor ADCs can produce hematologic and gastrointestinal toxicities, while auristatin-containing ADCs can be associated with peripheral neuropathy. Some agents have distinctive risks, such as interstitial lung disease with trastuzumab deruxtecan, requiring proactive monitoring and treatment interruption or discontinuation according to severity (4,7).

Precision safety therefore requires biomarker-guided efficacy to be paired with risk-adapted treatment. Dose and schedule optimization, early toxicity recognition, organ-function monitoring and patient education can materially influence the real-world therapeutic index. Future development is increasingly focused on randomized dose optimization, exposure-response modeling and identification of predictive biomarkers for serious adverse events (4,12).

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

3.5. Resistance mechanisms

ADC resistance is multifactorial because every step of the delivery pathway can fail. Tumors may reduce or heterogeneously express the target antigen, impair internalization, alter lysosomal trafficking, increase drug efflux or acquire resistance to the payload mechanism (13). Target heterogeneity is especially important because an ADC can be highly potent against antigen-rich cells while leaving antigen-low clones capable of driving relapse. Bystander-capable payloads partially address this problem but can also increase exposure of surrounding tissues. Resistance is therefore not a single molecular event but a systems-level property of tumor evolution and ADC pharmacology.

Next-generation ADCs attempt to address these limitations through bispecific antibodies, conditionally active antibodies, immune-stimulating payloads, protein-degrader payloads and dual-payload designs (3). Such constructs aim to increase selectivity, overcome heterogeneous expression or combine mechanistically distinct cytotoxic effects. However, added complexity can also increase manufacturing, analytical and regulatory challenges.




Figure 3. Major mechanisms of ADC resistance and safety failure with corresponding precision-development strategies.

4. DISCUSSION

The evidence supports a central conclusion: antibody therapeutics are most effective when the molecular format is matched to tumor biology rather than selected solely because a target is detectable. A naked antibody can be appropriate when blockade of signaling or Fc-mediated immune killing is sufficient. An ADC is preferable when the antigen

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

functions mainly as a delivery address and the therapeutic effect depends on intracellular release of a potent payload. Bispecific formats can be advantageous when dual engagement is biologically justified or when direct immune-cell redirection is required (1,11). This format-selection principle is fundamental to precision oncology.

Among ADCs, the relationship between target density and efficacy is no longer strictly linear. Newer agents with high drug loading, optimized linkers and membrane-permeable payloads can generate bystander killing and may retain activity in tumors with lower or heterogeneous antigen expression (3,7). Nevertheless, target distribution still matters because systemic expression on normal cells can narrow the therapeutic window. Thus, quantitative and spatial biomarker assessment may be more informative than a single binary pathology result. Emerging approaches such as digital pathology, single-cell profiling and longitudinal circulating-tumor DNA could help define which patients are likely to maintain target dependence over time.

A second key issue is the separation of efficacy from toxicity. The success of an ADC cannot be measured only by cytotoxic potency. Stable circulation, predictable conjugation, controlled DAR, limited nonspecific uptake and safe payload release are equally important. Clinical experience has shown that targeted delivery does not eliminate chemotherapy-like toxicities, and some severe adverse events are unique enough to require ADC-specific surveillance (4,12). For this reason, precision oncology should include precision dosing and toxicity prevention, not only biomarker-based drug selection.

Clinical resistance also argues for adaptive treatment strategies. Antigen loss after targeted therapy can reduce the value of reusing the same delivery address, while payload-specific resistance can make a different ADC against the same antigen ineffective if it uses a similar warhead. Re-biopsy or validated liquid-biopsy approaches may therefore be useful when resistance emerges. Sequencing strategies should consider both target and payload class, and combination approaches should have a mechanistic rationale rather than simply adding treatments (13-15).

The field is moving toward increasingly sophisticated constructs. Bispecific ADCs can potentially increase avidity or address heterogeneous tumors, dual-payload ADCs can attack complementary resistance pathways, and conditionally activated antibodies can reduce binding in healthy tissues (3). Site-specific conjugation may reduce product heterogeneity and improve pharmacokinetic consistency. At the same time, more complex constructs impose stricter requirements for manufacturing control, analytical characterization and long-term safety evaluation. The most successful next-generation ADCs will therefore likely be those that improve therapeutic index without creating unmanageable translational complexity.

Real-world precision also requires standardized toxicity surveillance. Baseline pulmonary assessment and rapid investigation of new respiratory symptoms are particularly important for ADCs associated with interstitial lung disease, while complete blood counts, hepatic function, neurologic examination and ocular monitoring may be appropriate for other platforms depending on payload and known toxicity profile. Patient education is an essential component because early reporting can convert a potentially severe toxicity into a manageable treatment interruption. Integrating toxicity biomarkers,

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

electronic symptom monitoring and pharmacokinetic modeling could eventually allow risk-adapted dosing strategies that are as personalized as biomarker-based drug selection (4).

Precision oncology extends beyond choosing the right molecule; it also includes selecting a dose and schedule that preserve benefit while minimizing cumulative toxicity. Because ADC exposure reflects both intact conjugate and released payload, conventional dose selection based only on body size can incompletely capture pharmacological variability. Exposure-response analyses, organ function, treatment-emergent toxicities and disease kinetics can support individualized decisions about dose interruption, reduction or re-escalation. Randomized dose optimization has become increasingly important in ADC development because a modest reduction in dose intensity may substantially improve tolerability without proportionally reducing antitumor activity in some settings (4,12).

4.2. DOSE OPTIMIZATION, MONITORING AND REAL-WORLD PRECISION

Treatment sequencing should also account for the history of target-directed exposure. A tumor progressing after a naked antibody may retain sufficient antigen for an ADC because the mechanisms of action are different; conversely, prior ADC treatment may select clones with antigen loss, altered trafficking or payload resistance. Reassessment of tumor biology at progression can therefore be informative, particularly when a new ADC targets the same antigen or uses a related cytotoxic warhead. In practice, sequencing decisions should integrate current antigen expression, previous response duration, prior toxicity, payload class and availability of alternative targets rather than relying only on the original diagnostic specimen (2,13-15).

Precision antibody therapy increasingly depends on quantitative rather than purely qualitative biomarker interpretation. Antigen positivity by immunohistochemistry does not necessarily indicate uniform target density across all tumor cells, metastatic sites or treatment time points. Spatial heterogeneity can be especially important for ADCs because intracellular payload delivery depends on the probability of antigen binding and internalization. The clinical activity of trastuzumab deruxtecan in HER2-low disease illustrates that therapeutic thresholds can change when ADC architecture changes, but it does not imply that any minimal antigen expression is sufficient. Biomarker thresholds should therefore be developed together with the specific antibody, linker and payload system, ideally using analytically validated assays and clinically relevant cut points (3,7,8).

4.1. BIOMARKER THRESHOLDS AND TREATMENT SEQUENCING

This review has limitations. It is a structured narrative synthesis rather than a systematic review or meta-analysis, and only a focused set of international sources was included. Clinical findings across different malignancies cannot be directly compared because target biology, patient selection, previous therapy and trial end points differ. Nevertheless, the selected literature captures key mechanistic, clinical and translational principles relevant to contemporary antibody-based precision oncology.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

Table 4. Major translational challenges and precision-development responses.

Challenge	Biological/clinical consequence	Potential precision response
Antigen heterogeneity	Incomplete tumor coverage and clonal escape	Spatial biomarker assessment, bystander-capable or dual-target ADCs
Linker instability	Premature payload release and systemic toxicity	More stable chemistry and site-specific conjugation
Payload resistance	Reduced intracellular killing	Switch payload mechanism or use rational dual-payload strategies
Severe class-specific toxicity	Dose interruption, discontinuation, morbidity	Risk stratification, active surveillance and exposure-guided dosing
Dynamic tumor evolution	Biomarker status changes over time	Repeat tissue/liquid profiling and adaptive sequencing

5. CONCLUSION

Monoclonal antibodies and antibody-drug conjugates are central technologies in precision cancer therapy because they convert tumor-associated molecular information into selective therapeutic action. Naked antibodies exploit signaling blockade and immune effector mechanisms, while ADCs combine antigen recognition with targeted delivery of potent cytotoxic payloads. Clinical experience with HER2-, TROP2- and Nectin-4-directed ADCs demonstrates that careful molecular engineering can extend the therapeutic reach of cancer biomarkers beyond traditional high-expression categories. At the same time, resistance, heterogeneous target expression, payload-specific toxicity and complex pharmacokinetics remain major barriers.

Future progress will depend on integrating molecular pathology with ADC engineering, exposure-response science and dynamic biomarker monitoring. Site-specific conjugation, optimized linkers, novel payload classes, bispecific and conditionally active constructs, and rational sequencing based on both target and payload biology are particularly promising. The practical goal is not maximal cytotoxicity, but the widest sustainable therapeutic index for the individual patient. This principle should guide the next phase of antibody-based precision oncology.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

REFERENCES

1. Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., et al. (2024). Cancer therapy with antibodies. Nature Reviews Cancer, 24, 399-426. https://doi.org/10.1038/s41568-024-00690-x
2. Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021). Unlocking the potential of antibody-drug conjugates for cancer therapy. Nature Reviews Clinical Oncology, 18, 327-344. https://doi.org/10.1038/s41571-021-00470-8
3. Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024). Exploring the next generation of antibody-drug conjugates. Nature Reviews Clinical Oncology, 21, 203-223. https://doi.org/10.1038/s41571-023-00850-2
4. Tarantino, P., Ricciuti, B., Pradhan, S. M., et al. (2023). Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nature Reviews Clinical Oncology, 20, 558-576. https://doi.org/10.1038/s41571-023-00783-w
5. Tsuchikama, K., & An, Z. (2018). Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein & Cell, 9(1), 33-46. https://doi.org/10.1007/s13238-016-0323-0
6. Jabbour, E., Paul, S., & Kantarjian, H. (2021). The clinical development of antibody-drug conjugates - lessons from leukaemia. Nature Reviews Clinical Oncology, 18, 418-433. https://doi.org/10.1038/s41571-021-00484-2
7. Modi, S., Jacot, W., Yamashita, T., et al. (2022). Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New England Journal of Medicine, 387, 9-20. https://doi.org/10.1056/NEJMoa2203690
8. Cortes, J., Kim, S.-B., Chung, W.-P., et al. (2022). Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. New England Journal of Medicine, 386, 1143-1154. https://doi.org/10.1056/NEJMoa2115022
9. Bardia, A., Hurvitz, S. A., Tolaney, S. M., et al. (2021). Sacituzumab govitecan in metastatic triple-negative breast cancer. New England Journal of Medicine, 384, 1529-1541. https://doi.org/10.1056/NEJMoa2028485
10. Powles, T., Rosenberg, J. E., Sonpavde, G. P., et al. (2021). Enfortumab vedotin in previously treated advanced urothelial carcinoma. New England Journal of Medicine, 384, 1125-1135. https://doi.org/10.1056/NEJMoa2035807
11. Goebeler, M.-E., Stuhler, G., & Bargou, R. (2024). Bispecific and multispecific antibodies in oncology: Opportunities and challenges. Nature Reviews Clinical Oncology, 21, 539-560. https://doi.org/10.1038/s41571-024-00905-y
12. Coats, S., Williams, M., Kebble, B., Dixit, R., Tseng, L., Yao, N.-S., Tice, D. A., & Soria, J.-C. (2019). Antibody-drug conjugates: Future directions in clinical and translational strategies to improve the therapeutic index. Clinical Cancer Research, 25(18), 5441-5448. https://doi.org/10.1158/1078-0432.CCR-19-0272
13. Loganzo, F., Sung, M., & Gerber, H.-P. (2016). Mechanisms of resistance to antibody-drug conjugates. Molecular Cancer Therapeutics, 15(12), 2825-2834. https://doi.org/10.1158/1535-7163.MCT-16-0408